CVSI
CV Sciences, Inc.
Next earnings Aug 11, 2026
Last earnings +0.0% on 2026-05-14
$0.02
▼ -16.67%$0.02▼ -33.33%
over 1Y
L $0.02EODHDH $0.09
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-16.7%
1W+4.8%
1M-20.0%
3M-20.0%
YTD-60.0%
1Y-20.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Revenue fell -12.2% YoY.
Revenue (FY2025) $13.8M · FY2025
CV Sciences, Inc. shows $13.8M in FY2025 revenue (-12.2% YoY), a -6.9% net margin, and -65.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $20.0M | $16.2M | $16.0M | $15.7M | $13.8M |
| Gross profit | $8.62M | $5.55M | $7.08M | $7.17M | $6.75M |
| Operating income | -$18.4M | -$6.85M | $3.36M | -$2.19M | -$470K |
| Net income | -$15.6M | -$8.21M | $3.10M | -$2.39M | -$958K |
| Diluted EPS | -$0.14 | -$0.07 | $0.02 | -$0.01 | -$0.01 |
| Net margin | -77.6% | -50.7% | 19.4% | -15.2% | -6.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.24M
EV / EBITDA—
EV / Sales0.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-24.8%
FCF yield-13.3%
Quality & risk
ROIC (est.)-11.9%
Free cash flow-$516K
Total debt$1.65M
Net cash-$1.37M
Altman Z-Score-15.48 distress
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+5.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2025-03-272026-06-04open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗DEF 14APeriod ending 2026-04-152026-04-15open ↗8-KPeriod ending 2026-04-062026-04-10open ↗10-KPeriod ending 2025-12-312026-03-26open ↗8-KPeriod ending 2026-03-262026-03-26open ↗8-KPeriod ending 2025-10-072026-03-10open ↗10-QPeriod ending 2025-09-302025-11-13open ↗8-KPeriod ending 2025-11-132025-11-13open ↗8-KPeriod ending 2025-10-072025-10-10open ↗8-KPeriod ending 2025-02-122025-09-18open ↗
Frequently asked
- Is CV Sciences, Inc. (CVSI) a buy?
- CVSI currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue fell -12.2% YoY.
- What is CV Sciences, Inc.'s quality score?
- CVSI scores 52.84313725490196/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001510964, latest 10-Q filed 2026-05-15) · EODHD · as of 6/24/2026, 2:28:31 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.